Quantoom Biosciences S.A. (“Quantoom”), a Univercells company, is establishing a team in the United States. The company has appointed Oladimeji Fashola as Chief Technology Officer, and Business Development team of three. These crucial additions mark an exciting phase of growth for the company and underline its commitment to expanding its presence in the U.S. market.
The fast development of effective COVID-19 vaccines has provided proof of concept to a promising platform modality that has the great potential to deliver many new, more effective, or more personalized medicines for patients in need. However, innovation in process development and manufacturing will be required to avoid bottlenecks in the swift and cost-effective progress of the growing and increasingly diverse candidate pipelines toward commercialization around the world.
“We are delighted to welcome Oladimeji and the new Business Development team to the Quantoom family,” said José Castillo, CEO of Quantoom Biosciences. “Their expertise, industry insight, and leadership will be instrumental in demonstrating the value of our innovation and in creating partnerships to advance our goal to accelerate the availability of new mRNA therapeutics and vaccines thanks to better, faster and more cost-effective process development and manufacturing.
Oladimeji Fashola brings extensive operations and strategic product lifecycle management experience in cell and gene therapy, RNA and recombinant protein manufacturing. He has been working in the biopharma industry for the past 15 years in roles, specializing process development, technology transfer, process qualification used to support clinical and commercialization and strategic sourcing.
“I am thrilled to join such a dynamic and forward-thinking company. Quantoom’s innovation in mRNA production aligns perfectly with my passion for technological progress for the benefit of patients. I am eager to contribute my expertise and collaborate with my like-minded new colleagues to accelerate the development and use of NfinityTM, Quantoom’s mRNA production platform”, said Oladimeji, Chief Technology Officer of Quantoom Biosciences.
Quantoom Biosciences Nfinity™ platform advances and accelerates cost-effective mRNA process development thanks to process intensification, integration and automation. It offers enhanced productivity and quality alongside seamless scaling, with reduced operational costs and capital investment needs.
Download the press release as a Pdf here.